Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
active pharmaceutical ingredient
|
| gptkbp:administrativeDivision |
weekly
|
| gptkbp:analyzes |
IND_application_submitted
|
| gptkbp:chemicalFormula |
small molecule
|
| gptkbp:clinicalTrials |
gptkb:Asterias_Biotherapeutics
gptkb:United_States Phase 1 pending Phase 2 to be determined multiple phases planned open-label study expected soon regularly published. |
| gptkbp:collaborations |
various research institutions
|
| gptkbp:community_service |
under investigation
overall survival |
| gptkbp:communityPartnerships |
with pharmaceutical companies
|
| gptkbp:compatibleWith |
enhances immune response
|
| gptkbp:contraindication |
monitored during trials
|
| gptkbp:currentStatus |
conducted
|
| gptkbp:customerFeedback |
collected during trials
|
| gptkbp:developedBy |
gptkb:Asterias_Biotherapeutics
|
| gptkbp:dosageForm |
determined in trials
|
| gptkbp:formulation |
injectable solution
|
| gptkbp:future_plans |
clinical trials
|
| gptkbp:hasPopulation |
diverse demographics
|
| gptkbp:healthcare |
specific criteria
ongoing during trials |
| gptkbp:historicalResearch |
expanding indications
|
| https://www.w3.org/2000/01/rdf-schema#label |
ASTX240
|
| gptkbp:investmentFocus |
high
|
| gptkbp:mandates |
solid tumors
|
| gptkbp:market |
high
|
| gptkbp:patentStatus |
patented
|
| gptkbp:productionCompany |
early phase
|
| gptkbp:regulatoryCompliance |
not approved
|
| gptkbp:relatedTo |
gptkb:Asterias_Biotherapeutics
|
| gptkbp:releaseYear |
2010
|
| gptkbp:research |
biopharmaceutical
various grants secured funding multi-year study |
| gptkbp:research_areas |
immuno-oncology
immunotherapy |
| gptkbp:researchAndDevelopment |
ongoing studies
|
| gptkbp:researchFocus |
oncology
|
| gptkbp:researchInterest |
patient recruitment
improve patient outcomes randomized trials with academic institutions published studies evaluate efficacy approved by ethics board novel approach to treatment potential to change treatment paradigms |
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
ongoing
under evaluation |
| gptkbp:sideEffect |
immune-related adverse events
|
| gptkbp:status |
investigational
|
| gptkbp:targets |
cancer
immune system patients with cancer |
| gptkbp:triggerType |
immune modulation
stimulates T-cells |
| gptkbp:usedFor |
cancer treatment
|